Tricida is a pharmaceutical company focused on its investigational drug candidate, veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal tract. Metabolic acidosis is a condition caused by chronic kidney disease, or CKD, which accelerate the progression of kidney deterioration as well as bone loss, muscle wasting and impaired physical function. Co.'s development program for veverimer include its ongoing VALOR-CKD trial, a 135-subject, Phase 1/2 trial, TRCA-101, a 217-subject, Phase 3 clinical trial, TRCA-301 and a 196-subject, Phase 3 extension trial, TRCA-301E. The TCDA stock yearly return is shown above.
The yearly return on the TCDA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TCDA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|